Should there be a standard therapy for mantle cell lymphoma?

Papers of special note have been highlighted as: ▪ of interest

Bibliography

• 1  Harris NL, Jaffe ES, Stein H et al.: A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood84,1361–1392 (1994).▪ First and succinct clinicopathologic description of mantle cell lymphoma (MCL).
  Medline CASGoogle Scholar
• 2  A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N. Engl. J. Med.329,987–994 (1993).
  MedlineGoogle Scholar
• 3  Solal-Celigny P, Roy P, Colombat P et al.: Follicular lymphoma international prognostic index. Blood104,1258–1265 (2004).
  Medline CASGoogle Scholar
• 4  Hoster E, Dreyling M, Klapper W et al.: A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood111,558–565 (2008).▪ Best prognostic index to date, particularly if Ki-67 proliferation results are included.
  Medline CASGoogle Scholar
• 5  Herrmann A, Hoster E, Zwingers T et al.: Improvement of overall survival in advanced stage mantle cell lymphoma. J. Clin. Oncol.27,511–518 (2009).▪ A more realistic appraisal of expected survival shows that MCL is not as poor a prognosis as often quoted, and this is already old information that probably underestimates current outcomes.
  MedlineGoogle Scholar
• 6  Martin P, Chadburn A, Christos P et al.: Outcome of deferred initial therapy in mantle-cell lymphoma. J. Clin. Oncol.27,1209–1213 (2009).
  MedlineGoogle Scholar
• 7  Fernandez V, Salamero O, Espinet B et al.: Genomic and gene expression profiling defines indolent forms of mantle-cell lymphoma. Cancer Res.70,1408–1418 (2010).
  Medline CASGoogle Scholar
• 8  Williams ME, Swerdlow SH: Cyclin D1 overexpression in non-Hodgkin’s lymphoma with chromosome 11 bcl-1 rearrangement. Ann. Oncol.5,71–73 (1994).
  MedlineGoogle Scholar
• 9  Rosenwald A, Wright G, Wiestner A et al.: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle-cell lymphoma. Cancer Cell3,185–197 (2003).
  Medline CASGoogle Scholar
• 10  Fu K, Weisenburger DD, Greiner TC et al.: Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood106,4315–4321 (2005).
  Medline CASGoogle Scholar
• 11  O’Connor OA, Moskowitz C, Portlock C et al.: Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase II clinical trial. Br. J. Haematol.145,34–39 (2009).
  MedlineGoogle Scholar
• 12  Pro B, Leber B, Smith M et al.: Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br. J. Haematol.143,355–360 (2008).
  Medline CASGoogle Scholar
• 13  Hwang JJ, Kuruvilla J, Mendelson D et al.: Phase I dose finding studies of obatoclax (GX15–070), a small molecule Pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin. Cancer Res.16,4038–4045 (2010).
  Medline CASGoogle Scholar
• 14  Wilson WH, O’Connor OA, Czuczman MS et al.: Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a Phase I dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol.11,1149–1159 (2010).
  Medline CASGoogle Scholar
• 15  Younes A, Vose JM, Zelenetz AD et al.: A Phase Ib/II trial of mapatumumab in patients with relapsed/refractory non-Hodgkin’s lymphoma. 103,1783–1787 (2010).
  Google Scholar
• 16  Spurgeon S, Yu M, Phillips JD, Epner EM: Cladribine: not just another purine analogue? Exp. Opin. Invest. Drugs.18,1169–1181 (2009).
  Medline CASGoogle Scholar
• 17  Inwards DJ, Fishkin PAS, Hillman DW et al.: Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95–80–53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer113,108–116 (2008).
  Medline CASGoogle Scholar
• 18  Rummel MJ, Chow KU, Jäger E et al.: Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas. Leuk. Lymph.35,129–138 (1999).
  Medline CASGoogle Scholar
• 19  Leshchenko VV, Kuo P-Y, Shaknovich R et al.: Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood116,1025–1034 (2010).
  Medline CASGoogle Scholar
• 20  Wang X, Asplund AC, Porwit A et al.: The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br. J. Haematol.143,248–252 (2008).
  MedlineGoogle Scholar
• 21  Hartmann E, Fernàndez V, Moreno V et al.: Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J. Clin. Oncol.26,4966–4972 (2008).
  MedlineGoogle Scholar
• 22  Determann O, Hoster E, Ott G et al.: Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood111,2385–2387 (2008).
  Medline CASGoogle Scholar
• 23  Tiemann M, Schrader C, Klapper W et al.: Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br. J. Haematol.131,29–38 (2005).
  MedlineGoogle Scholar
• 24  Schaffel R, Hedvat CV, Teruya-Feldstein J et al.: Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann. Oncol.21,133–139 (2010).
  Medline CASGoogle Scholar
• 25  Howard OM, Gribben JG, Neuberg DS et al.: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J. Clin. Oncol.20,1288–1294 (2002).
  Medline CASGoogle Scholar
• 26  Lenz G, Dreyling MH, Hoster E et al.: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J. Clin. Oncol.23 (2005).
  Google Scholar
• 27  Dreyling M, Lenz G, Hoster E et al.: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood105,2677–2684 (2005).
  Medline CASGoogle Scholar
• 28  Khouri I, Romaguera J, Kantarjian H et al.: Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J. Clin. Oncol.16,3803–3809 (1998).
  Medline CASGoogle Scholar
• 29  Romaguera JE, Fayad L, Rodriguez MA et al.: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J. Clin. Oncol.23,7013–7023 (2005).
  Medline CASGoogle Scholar
• 30  Epner EM Unger JM, Miller T et al.: A multicenter trial of hyperCVAD plus rituxan in patients with newly diagnosed mantle cell lymphoma. Blood110,A387 (2007).
  Google Scholar
• 31  Merli F, Luminari S, Ilariucci F et al.: Rituximab plus HyperCVAD alternating with high dose methotrexate and cytarabine for patients with newly diagnosed mantle cell lymphoma. A multicenter trial from GISL. Blood112,A3050 (2008).
  Google Scholar
• 32  LeCasce A, Vandergrift JL, Rodriguez MA et al.: R-CHOP, followed by high dose therapy and autologous stem cell rescue (HDT/ASCR), and R-HyperCVAD have equivalent progression-free survival and are superior to R-CHOP alone in younger patients with mantle cell lymphoma: a comparative effectiveness analysis from the National Comprehensive Cancer Network (NCCN) non-Hodgkin’s lymphoma outcomes database project. Blood114,A403 (2009).
  Google Scholar
• 33  Ganti AK, Bierman PJ, Lynch JC, Bociek RG, Vose JM, Armitage JO: Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann. Oncol.16,618–624 (2005).
  Medline CASGoogle Scholar
• 34  Geisler CH, Kolstad A, Laurell A et al.: Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized Phase II multicenter study by the Nordic Lymphoma Group. Blood112,2687–2693 (2008).▪ Innovative approach combining dose-intensified induction, including high-dose cytarabine and rituximab, and autologous stem cell transplant consolidation, with post-stem cell transplant molecular relapses treated with rituximab. Outcomes are encouraging for these younger patients and longer follow-up will be important.
  Medline CASGoogle Scholar
• 35  Schulz H, Bohlius JF, Trelle S et al.: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J. Natl Cancer Inst.99,706–714 (2007).
  Medline CASGoogle Scholar
• 36  Hermine O, Hoster E, Walewski J et al.: Alternating courses of 3 × CHOP and 3 × DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to six courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL Net). Blood116,A110 (2010).▪ Only in abstract form so far, but describes the potential for R-CHOP alternating with R-DHAP to become a standard pre-stem cell transplant induction. Shares some similarities in design with the Nordic trial [34], but is a regimen familiar to most oncologists.
  Google Scholar
• 37  Pott C, Hoster E, Beldjord K et al.: R-CHOP/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL Younger Intergroup Trial of the European MCL Network. Blood116,A965 (2010).
  Google Scholar
• 38  Damon LE, Johnson JL, Niedzwiecki D et al.: Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J. Clin. Oncol.27,6101–6108 (2009).
  Medline CASGoogle Scholar
• 39  Romaguera JE, Fayad LE, Feng L et al.: Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br. J. Haematol.150,200–208 (2010).▪ Despite the concerns regarding single-center data and patient selection, these data are still the gold-standard for comparison with new treatment strategies in young, fit patients.
  Medline CASGoogle Scholar
• 40  Meusers P, Engelhard M, Bartels H et al.: Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol. Oncol.7,365–380 (1989).
  Medline CASGoogle Scholar
• 41  Smith MR, Gordon LI, Foran J et al.: Phase II study of R-CHOP followed by 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499. Blood110,A389 (2007).
  Google Scholar
• 42  Kahl BS, Longo WL, Eickhoff JC et al.: Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann. Oncol.17,1418–1423 (2006).
  Medline CASGoogle Scholar
• 43  Kahl BS, Li H, Smith MR et al.: The VcR-CVAD regimen produces a high complete response rate in untreated mantle cell lymphoma (MCL): first analysis of E1405 – a Phase II study of VcR-CVAD with maintenance rituximab for MCL. Blood114,A1661 (2009).
  Google Scholar
• 44  Rummel MJ, Al-Batran SE, Kim S-Z et al.: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J. Clin. Oncol.23,3383–3389 (2005).
  Medline CASGoogle Scholar
• 45  Robinson KS, Williams ME, van der Jagt RH et al.: Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J. Clin. Oncol.26,4473–4479 (2008).
  Medline CASGoogle Scholar
• 46  Rummel MJ, Niederle N, Maschmeyer G et al.: Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized Phase III study of the STIL (Study Group Indolent Lymphomas, Germany). Blood114,A405 (2009).▪ While we await the peer-reviewed publication for details, such as the MCL patient characteristics, for MCL these data represent a large randomized cohort and demonstrate superiority of bendamustine–rituximab to R-CHOP, forming the basis for new studies.
  Google Scholar
• 47  Furman RR, Martin P, Ruan J et al.: Phase I trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer116(23),5432–5439 (2010).
  Medline CASGoogle Scholar
• 48  Friedberg JW, Vose JM, Kelly JL et al.: Bendamustine, bortezomib and rituximab in patients (pts) relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (NHL): a multicenter Phase II clinical trial. Blood114,A924 (2009).
  Google Scholar
• 49  Fowler N KB, Rosen P, Matous J et al.: Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: encouraging activity in the Phase 2 VERTICAL study. Blood114,A933 (2009).
  MedlineGoogle Scholar
• 50  Ganjoo KN, An CS, Robertson MJ et al.: Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk. Lymph.47,998–1005 (2006).
  Medline CASGoogle Scholar
• 51  Forstpointner R, Unterhalt M, Dreyling M et al.: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood108,4003–4008 (2006).
  Medline CASGoogle Scholar
• 52  Kahl BS, Williams ME, Hong F, Gascoyne R, Horning SJ: Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Retreatment Trial (RESORT). Blood110,A3420 (2007).
  Google Scholar
• 53  Ghielmini M, Schmitz SF, Cogliatti SB et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × four schedule. Blood103,4416–4423 (2004).
  Medline CASGoogle Scholar
• 54  Habermann TM, Lossos IS, Justice G et al.: Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br. J. Haematol.145,344–349 (2009).
  Medline CASGoogle Scholar
• 55  Wu L, Adams M, Carter T et al.: Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20⁺ tumor cells. Clin. Cancer Res.14,4650–4657 (2008).
  Medline CASGoogle Scholar
• 56  Zhang L, Qian Z, Cai Z et al.: Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am. J. Hematol.84,553–559 (2009).
  Medline CASGoogle Scholar
• 57  Wang M, Oki Y, Pro B et al.: Phase II study of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol.27,5213–5218 (2009).
  Medline CASGoogle Scholar
• 58  Gopal AK, Rajendran JG, Gooley TA et al.: High-dose [¹³¹I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J. Clin. Oncol.25,1396–1402 (2007).
  MedlineGoogle Scholar
• 59  Krishnan A, Nademanee A, Fung HC et al.: Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma. J. Clin. Oncol.26,90–95 (2008).
  Medline CASGoogle Scholar
• 60  Kaufmann H, Raderer M, Wohrer S et al.: Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood104,2269–2271 (2004).
  Medline CASGoogle Scholar
• 61  Witzig TE, Geyer SM, Ghobrial I et al.: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol.23,5347–5356 (2005).
  Medline CASGoogle Scholar
• 62  Haritunians T, Mori A, O’Kelly J, Luong QT, Giles FJ, Koeffler HP: Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. 21,333–339 (2006).
  Google Scholar
• 63  Lenz G, Hiddemann W, Dreyling M: The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer101,883–893 (2004).
  Medline CASGoogle Scholar
• 64  Leonard JP, LaCasce A, Smith MR et al.: Cdk4/6 inhibitor PD 0332991 demonstrates cell cycle inhibition via FLT-PET imaging and tissue analysis in patients with recurrent mantle-cell lymphoma. Blood112,A264 (2008).
  MedlineGoogle Scholar
• 65  Tam CS, Bassett R, Ledesma C et al.: Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood113,4144–4152 (2009).
  Medline CASGoogle Scholar
• 66  Maris MB, Sandmaier BM, Storer BE et al.: Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood104,3535–3542 (2004).
  Medline CASGoogle Scholar
• 67  Shanbhag S, Smith MR, Emmons RVB: Tackling mantle cell lymphoma: potential benefit of allogeneic stem cell transplantation. Stem. Cell Clon. Adv. Appl.3,93–102 (2010).
  Medline CASGoogle Scholar